Allergan Inc's "inaccurate and misleading statements" and unsupported arguments about Valeant Pharmaceuticals Inc leaves Valeant no choice but to take its $53 billion takeover offer directly to Allergan shareholders, Valeant said on Tuesday. Allergan's board has been unwilling to meet with Valeant, which it must do to properly gauge the value of Valeant's offer, spokeswoman Laurie Little said in a statement. Allergan rejected Valeant's most recent offer earlier in the day.
Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. Shares of AGN traded higher by 0.17% or $0.275/share to $164.42. In the past year, the shares have traded as low as $81.33 and as high as $172.48. On average, 4636580 shares of AGN exchange hands on a given day and today's volume is recorded at 1002801.
Source
